Eiji Iwama

2.8k total citations · 2 hit papers
70 papers, 1.9k citations indexed

About

Eiji Iwama is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Eiji Iwama has authored 70 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Pulmonary and Respiratory Medicine, 42 papers in Oncology and 16 papers in Molecular Biology. Recurrent topics in Eiji Iwama's work include Lung Cancer Treatments and Mutations (46 papers), Lung Cancer Research Studies (17 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Eiji Iwama is often cited by papers focused on Lung Cancer Treatments and Mutations (46 papers), Lung Cancer Research Studies (17 papers) and Cancer Immunotherapy and Biomarkers (14 papers). Eiji Iwama collaborates with scholars based in Japan, United States and China. Eiji Iwama's co-authors include Yoichi Nakanishi, Isamu Okamoto, Keiichi Ota, Koichi Takayama, Koichi Azuma, Taishi Harada, Koichiro Matsumoto, Tomoaki Hoshino, Satoshi Hattori and Shinzo Takamori and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Scientific Reports.

In The Last Decade

Eiji Iwama

66 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

2014 525 citations Koichi Azuma, Keiichi Ota et al. profile →
Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer

2015 366 citations Keiichi Ota, Koichi Azuma et al. Clinical Cancer Research profile →

Peers

Eiji Iwama

ONCOL

PRM

IMMUN

M. Ratcliffe United Kingdom

Paula I. González-Ericsson United States

Haoquan Zhao United States

Martín A. Rivas Argentina

Pamela Villalobos United States

Roxanne Toivanen Australia

Reika Iwakawa Japan

Jia Zhong China

Colin R. Lindsay United Kingdom

Yoshio Tomizawa Japan

M. Ratcliffe United Kingdom

Eiji Iwama

680 ×0.5

ONCOL

661 ×0.5

PRM

619 ×1.5

411 ×1.2

198 ×0.6

IMMUN

Citations per year, relative to Eiji Iwama Eiji Iwama (= 1×) peers M. Ratcliffe

Countries citing papers authored by Eiji Iwama

Since Specialization

Citations

This map shows the geographic impact of Eiji Iwama's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eiji Iwama with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eiji Iwama more than expected).

Fields of papers citing papers by Eiji Iwama

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eiji Iwama. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eiji Iwama. The network helps show where Eiji Iwama may publish in the future.

Co-authorship network of co-authors of Eiji Iwama

This figure shows the co-authorship network connecting the top 25 collaborators of Eiji Iwama. A scholar is included among the top collaborators of Eiji Iwama based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eiji Iwama. Eiji Iwama is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kanda, Shintaro, Seiji Niho, Takayasu Kurata, et al.. (2025). Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation. Clinical Cancer Research. 31(12). 2317–2326. 1 indexed citations

Nakashima, Kazuki, et al.. (2025). Suitability of Frozen Pleural Fluid Pellets for Next‐Generation Sequencing‐Based Driver Gene Testing in Non‐Small Cell Lung Cancer. Thoracic Cancer. 16(11). e70107–e70107.

Otsubo, Kohei, et al.. (2025). Remarkable response to crizotinib in a patient with advanced lung adenocarcinoma harboring the MPRIP-ROS1 fusion gene: A case report. Respiratory Medicine Case Reports. 56. 102243–102243.

Iwama, Eiji, et al.. (2024). TP53 gain-of-function mutations promote osimertinib resistance via TNF-α–NF-κB signaling in EGFR-mutated lung cancer. npj Precision Oncology. 8(1). 60–60. 13 indexed citations

Yamamoto, Yoshihiro, Kohei Otsubo, Yoshimasa Shiraishi, et al.. (2024). Tracheomediastinal fistula induced by concurrent chemoradiotherapy in small cell lung cancer: A case report and literature review. Thoracic Cancer. 15(13). 1106–1111. 1 indexed citations

Yoneshima, Yasuto, Koji Okamura, Toyoshi Yanagihara, et al.. (2023). MicroRNA‐326 negatively regulates CD155 expression in lung adenocarcinoma. Cancer Science. 114(10). 4101–4113. 4 indexed citations

Inoue, Hiroyuki, Yoshimasa Shiraishi, Hiroyuki Ando, et al.. (2023). Impact of increased plasma levels of calreticulin on prognosis of patients with advanced lung cancer undergoing combination treatment of chemotherapy and immune checkpoint inhibitors. Lung Cancer. 181. 107264–107264. 8 indexed citations

Iwama, Eiji, Hidetaka Yamamoto, Kayo Ijichi, et al.. (2023). Evaluation of appropriate conditions for Oncomine DxTT testing of FFPE specimens for driver gene alterations in non–small cell lung cancer. Thoracic Cancer. 14(23). 2288–2296. 4 indexed citations

Tanaka, Kentaro, et al.. (2023). YAP mediates resistance to EGF-induced apoptosis in EGFR-mutated non-small cell lung cancer cells. Biochemical and Biophysical Research Communications. 681. 120–126.

10.

Okamura, Koji, Hiroyuki Inoue, Kentaro Tanaka, et al.. (2022). Immunostimulatory oncolytic activity of coxsackievirus A11 in human malignant pleural mesothelioma. Cancer Science. 114(3). 1095–1107. 5 indexed citations

11.

Iwama, Eiji, Keiichi Ota, Hiroyuki Inoue, et al.. (2022). Mutant forms of EGFR promote HER2 trafficking through efficient formation of HER2-EGFR heterodimers. Lung Cancer. 175. 101–111. 5 indexed citations

12.

Liu, Renpeng, Keiichi Ota, Eiji Iwama, et al.. (2021). Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non–small cell lung cancer patients treated with osimertinib. Lung Cancer. 158. 156–161. 4 indexed citations

13.

Tanaka, Kentaro, Gouji Toyokawa, Kayo Ijichi, et al.. (2020). NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration. Lung Cancer. 146. 97–104. 22 indexed citations

14.

Ogata, Hiroaki, Isamu Okamoto, Goichi Yoshimoto, et al.. (2017). Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Respiratory Investigation. 55(2). 181–183. 2 indexed citations

15.

Kawano, Yuko, Eiji Iwama, Kenji Tsuchihashi, et al.. (2017). CD44 variant–dependent regulation of redox balance in EGFR mutation–positive non–small cell lung cancer: A target for treatment. Lung Cancer. 113. 72–78. 10 indexed citations

16.

Iwama, Eiji, Isamu Okamoto, Hidetake Yabuuchi, et al.. (2016). Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae. Journal of Thoracic Oncology. 11(9). 1586–1590. 11 indexed citations

17.

Ota, Keiichi, Koichi Azuma, Akihiko Kawahara, et al.. (2015). Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer. Clinical Cancer Research. 21(17). 4014–4021. 366 indexed citations breakdown →

18.

Li, Heyan, Shuo Wang, Koichi Takayama, et al.. (2015). Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model. Lung Cancer. 88(1). 1–8. 32 indexed citations

19.

Yoneshima, Yasuto, Isamu Okamoto, Shinichi Kimura, et al.. (2014). Infected complex renal cysts during crizotinib therapy in a patient with non–small cell lung cancer positive for ALK rearrangement. Investigational New Drugs. 33(2). 510–512. 9 indexed citations

20.

Furuyama, Kazuto, Taishi Harada, Eiji Iwama, et al.. (2013). Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR‐tyrosine kinase inhibitors. Cancer Science. 104(5). 584–589. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact